Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 20 December 2025 - 23 December 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly shares closed up 0.47% at $1,076.48 Monday, then fell about 1% in after-hours trading after the FDA approved Novo Nordisk’s Wegovy weight-loss pill. Novo’s U.S. shares jumped roughly 6% following the news. The new oral semaglutide is the first FDA-cleared pill for obesity, with Novo saying it will launch early next year at $149 a month. Lilly’s own oral obesity drug, orforglipron, could be approved as soon as late March.
23 December 2025
····
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie shares traded at $227.73 midday Monday, near recent highs, as the company remains one of three major drugmakers not signed onto the White House’s new “most-favored-nation” drug-pricing agreements announced December 19. Investors are watching for AbbVie’s next move on the policy front, while its core immunology drugs and dividend growth continue to anchor fundamentals.
22 December 2025
···
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen shares rose to around $331 on December 22, 2025, after the White House announced drug-pricing deals with major drugmakers, including Amgen. The company will offer Aimovig and Amjevita at $299 per month through direct-to-patient sales. Analysts said the agreements may ease tariff and political risks but are unlikely to significantly affect pharma profits in the near term.
22 December 2025
··
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals joined the Nasdaq-100 Index on Dec. 22, 2025, as the annual reconstitution took effect before the market opened. Shares traded near $405.60, up 1.3% from the prior close. The company recently announced a $250 million U.S. manufacturing expansion and reported strong adoption of its AMVUTTRA therapy for transthyretin amyloidosis.
22 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer on Dec. 22 announced a new metastatic prostate cancer research program with Flagship Pioneering and Repertoire Immune Medicines, the eighth under their alliance. The move follows Pfizer’s Dec. 16 guidance projecting flat-to-down 2026 revenue, ongoing COVID product declines, and increased R&D spending. Management warned of “bumpy” years ahead as exclusivity losses weigh on sales.
22 December 2025
····
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie closed at $226.82 on Friday, Dec. 19, up 1.8%, with trading volume spiking to 18.6 million shares, well above average. The company remains in talks with the White House as U.S. drug pricing reforms accelerate, including “most-favored-nation” deals and new TrumpRx programs. AbbVie is expected to visit the White House after the holidays for further negotiations.
22 December 2025
···
Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, as new late-stage data for oral GLP-1 candidate orforglipron showed less weight regain versus placebo after switching from injectables. Retatrutide posted 28.7% average weight loss in a Phase 3 trial. Lilly cut Zepbound prices in the U.S. and Canada. Orforglipron could receive FDA approval as early as March 2026.
22 December 2025
··
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie shares closed at $226.82 on Friday, December 19, up 1.8% on heavy volume ahead of a holiday-shortened week. The company was not included in the White House’s December 19 list of drugmakers agreeing to new MFN pricing deals, leaving policy risk unresolved. Investors are watching for further announcements that could affect sentiment and trading.
21 December 2025
··
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson closed Friday, Dec. 19, 2025, at about $206 per share, as investors weighed U.S. drug-pricing negotiations and new talc verdicts against product pipeline momentum. The company is set to meet with the White House after the holidays over possible participation in the TrumpRx drug-pricing initiative. Trading volume is expected to be thin during the Christmas-shortened week.
21 December 2025
··
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 4.3% from the previous week. The company’s stock remains near record highs as late-stage trial data showed its oral obesity drug orforglipron helped patients maintain weight loss after switching from injectables. Reuters reported the FDA is considering a faster review timeline for orforglipron.
21 December 2025
··
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals (RXRX) closed at $4.26 on December 19, 2025, with a market cap of about $2.1 billion after releasing Phase 1b/2 data for REC‑4881 in familial adenomatous polyposis. The trial showed a median 43% reduction in polyp burden at 13 weeks and 53% at 25 weeks. REC‑4881 has Fast Track and Orphan Drug status from the FDA and EU. Trading volume was heavy, with sentiment split on commercialization prospects.
21 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer shares closed at $25.19 on Dec. 19, down 4.7% from earlier in the week after the company issued 2026 guidance projecting flat or lower reported results. The company expects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Market cap stands near $114 billion.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie shares closed at $226.82 on Friday, up 1.8%, nearing a 52-week high with a market cap near $400 billion. U.S. drug pricing policy returned to focus after the Trump administration announced agreements with nine drugmakers, excluding AbbVie, which remains in upcoming negotiations. New Medicare pilot programs tied to international price referencing were also announced. Trading volume approached 19 million shares.
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

A Minnesota jury awarded $65.5 million to a plaintiff who said Johnson & Johnson’s talc products caused mesothelioma, with J&J vowing to appeal. JNJ shares last traded at $206.37, down 0.9% from the prior close and about 3.6% below their December 15 record. Over 67,000 plaintiffs are suing J&J over similar claims. The company declared a $1.30 quarterly dividend for Q4 2025.
20 December 2025
·
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, after reporting positive Phase 3 results for its oral weight-loss drug orforglipron. The company also cut prices on Zepbound and Mounjaro in the U.S. and Canada. Lilly’s market value surpassed $1 trillion this year amid growing demand for obesity and cardiometabolic treatments.
20 December 2025
···
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer shares closed at $25.19 after a volatile week marked by a sharp selloff following new 2026 guidance. The company forecasted 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with COVID-19 product sales expected to drop further. Management signaled no return to revenue growth until 2029, citing patent expirations and pricing pressures.
20 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals closed up 1.97% at $456.20 Friday, ending a three-day slide on volume of about 5.56 million shares, far above its 50-day average. After-hours trading was quiet, with the stock quoted near $456.49 as of 7:40 p.m. ET. No major company news drove the move; trading reflected broad market gains and heavy year-end positioning.
20 December 2025
··
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences shares jumped 2.3% to $124.29 Friday after the company announced a three-year U.S. drug pricing deal tied to TrumpRx.gov and tariff relief, plus new U.K. approval for lenacapavir. Trading volume spiked to 24.39 million shares. After-hours, the stock edged up to $124.78. The White House said Epclusa’s U.S. price will drop from $24,920 to $2,425 under the new agreement.
20 December 2025
··
1 … 23 24 25 26 27 … 38

Stock Market Today

  • Dow, S&P 500, Nasdaq futures dip as financial sector stumbles on private credit risks
    April 11, 2026, 10:02 AM EDT. Dow, S&P 500, and Nasdaq futures edged lower as the financial sector suffered heavy losses, led by insurance stocks. Shares of Ares, Arthur J. Gallagher, Aon, and Willis Towers Watson dropped after a report from rating firm A.M. Best warned of growing risks tied to private credit in insurers' balance sheets. The report highlighted vulnerabilities in annuity products, which now often rely on lower-quality, less transparent issuers, including overseas affiliates. It noted a surge in private equity-backed insurers entering the annuity market, attracted by the spread between premia inflows and crediting rates fueled by private credit returns. Rising concerns about the quality and stability of private credit investments are prompting analysts to flag new financial system risks amid broader economic and geopolitical instability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 10:12 AM EDT Best Dividend Stock to Buy with $5,000: Coca-Cola (KO) Offers Reliable Income April 11, 2026, 10:12 AM EDT. Investors seeking steady income can consider buying Coca-Cola (NYSE: KO) with $5,000, acquiring about 66 shares at $75.91 each. The beverage giant recently raised its quarterly dividend to $0.53, marking its 64th consecutive annual increase. This longevity highlights Coca-Cola's commitment to shareholders and dividend sustainability, driven by its strong brand and stable market position. While Coca-Cola's 10-year total return trails the broader S&P 500 index, it remains
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop